Barbituric acid, 5-allyl-

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581610

CAS#: 2565-43-7

Description: Barbituric acid, 5-allyl-, arbituric acid is discontinued (DEA controlled substance). It is an odourless powder and is soluble in water. It has a very high pharmacological activity and can be used to synthesize addition derivatives of it, to be used in novel drug discovery. It basically acts on the central nervous system (CNS) depressants, thereby possessing a wide range from mild sedation to total anaesthesia.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-26. Prices are subject to change without notice.

Barbituric acid, 5-allyl- is discontinued (DEA controlled substance).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 581610
Name: Barbituric acid, 5-allyl-
CAS#: 2565-43-7
Chemical Formula: C7H8N2O3
Exact Mass: 168.0535
Molecular Weight: 168.15
Elemental Analysis: C, 50.00; H, 4.80; N, 16.66; O, 28.54

Synonym: Barbituric acid, 5-allyl-; 5-Allylbarbituric acid; 5-Allyl-2,4,6-pyrimidinetrione; Deallylallobarbitone.

IUPAC/Chemical Name: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(2-propenyl)-


InChi Code: InChI=1S/C7H8N2O3/c1-2-3-4-5(10)8-7(12)9-6(4)11/h2,4H,1,3H2,(H2,8,9,10,11,12)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: McGrath M, Yu Z, Jayakar SS, Ma C, Tolia M, Zhou X, Miller KW, Cohen JB, Raines DE. Etomidate and Etomidate Analog Binding and Positive Modulation of γ-Aminobutyric Acid Type A Receptors: Evidence for a State-dependent Cutoff Effect. Anesthesiology. 2018 Nov;129(5):959-969. doi: 10.1097/ALN.0000000000002356. PubMed PMID: 30052529.

2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from PubMed PMID: 30000541.

3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from PubMed PMID: 30000446.

4: Feng HJ, Forman SA. Comparison of αβδ and αβγ GABA(A) receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics. Pharmacol Res. 2018 Jul;133:289-300. doi: 10.1016/j.phrs.2017.12.031. Epub 2017 Dec 30. Review. PubMed PMID: 29294355; PubMed Central PMCID: PMC6026480.

5: Yu Z, Cohen JB. Enantiomeric barbiturates bind distinct inter- and intrasubunit binding sites in a nicotinic acetylcholine receptor (nAChR). J Biol Chem. 2017 Oct 20;292(42):17258-17271. doi: 10.1074/jbc.M117.808592. Epub 2017 Sep 6. PubMed PMID: 28878016; PubMed Central PMCID: PMC5655505.

6: Ma C, Pejo E, McGrath M, Jayakar SS, Zhou X, Miller KW, Cohen JB, Raines DE. Competitive Antagonism of Anesthetic Action at the γ-Aminobutyric Acid Type A Receptor by a Novel Etomidate Analog with Low Intrinsic Efficacy. Anesthesiology. 2017 Nov;127(5):824-837. doi: 10.1097/ALN.0000000000001840. PubMed PMID: 28857763; PubMed Central PMCID: PMC5645246.

7: Nourmahnad A, Stern AT, Hotta M, Stewart DS, Ziemba AM, Szabo A, Forman SA. Tryptophan and Cysteine Mutations in M1 Helices of α1β3γ2L γ-Aminobutyric Acid Type A Receptors Indicate Distinct Intersubunit Sites for Four Intravenous Anesthetics and One Orphan Site. Anesthesiology. 2016 Dec;125(6):1144-1158. PubMed PMID: 27753644; PubMed Central PMCID: PMC5117677.

8: Stern AT, Forman SA. A Cysteine Substitution Probes β3H267 Interactions with Propofol and Other Potent Anesthetics in α1β3γ2L γ-Aminobutyric Acid Type A Receptors. Anesthesiology. 2016 Jan;124(1):89-100. doi: 10.1097/ALN.0000000000000934. PubMed PMID: 26569173; PubMed Central PMCID: PMC4681607.

9: Jayakar SS, Zhou X, Savechenkov PY, Chiara DC, Desai R, Bruzik KS, Miller KW, Cohen JB. Positive and Negative Allosteric Modulation of an α1β3γ2 γ-Aminobutyric Acid Type A (GABAA) Receptor by Binding to a Site in the Transmembrane Domain at the γ+-β- Interface. J Biol Chem. 2015 Sep 18;290(38):23432-46. doi: 10.1074/jbc.M115.672006. Epub 2015 Jul 30. PubMed PMID: 26229099; PubMed Central PMCID: PMC4645599.

10: Jayakar SS, Zhou X, Chiara DC, Dostalova Z, Savechenkov PY, Bruzik KS, Dailey WP, Miller KW, Eckenhoff RG, Cohen JB. Multiple propofol-binding sites in a γ-aminobutyric acid type A receptor (GABAAR) identified using a photoreactive propofol analog. J Biol Chem. 2014 Oct 3;289(40):27456-68. doi: 10.1074/jbc.M114.581728. Epub 2014 Aug 1. PubMed PMID: 25086038; PubMed Central PMCID: PMC4183786.

11: Hamouda AK, Stewart DS, Chiara DC, Savechenkov PY, Bruzik KS, Cohen JB. Identifying barbiturate binding sites in a nicotinic acetylcholine receptor with [3H]allyl m-trifluoromethyldiazirine mephobarbital, a photoreactive barbiturate. Mol Pharmacol. 2014 May;85(5):735-46. doi: 10.1124/mol.113.090985. Epub 2014 Feb 21. PubMed PMID: 24563544; PubMed Central PMCID: PMC3990015.

12: Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW, Cohen JB. Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human α1β3γ2 γ-aminobutyric acid type A (GABAA) receptor. J Biol Chem. 2013 Jul 5;288(27):19343-57. doi: 10.1074/jbc.M113.479725. Epub 2013 May 15. PubMed PMID: 23677991; PubMed Central PMCID: PMC3707639.

13: Savechenkov PY, Zhang X, Chiara DC, Stewart DS, Ge R, Zhou X, Raines DE, Cohen JB, Forman SA, Miller KW, Bruzik KS. Allyl m-trifluoromethyldiazirine mephobarbital: an unusually potent enantioselective and photoreactive barbiturate general anesthetic. J Med Chem. 2012 Jul 26;55(14):6554-65. doi: 10.1021/jm300631e. Epub 2012 Jul 17. PubMed PMID: 22734650; PubMed Central PMCID: PMC3717557.

14: Gelbrich T, Zencirci N, Griesser UJ. Hydrogen-bond motifs in N-monosubstituted derivatives of barbituric acid: 5-allyl-5-isopropyl-1-methylbarbituric acid (enallylpropymal) and 1,5-di(but-2-enyl)-5-ethylbarbituric acid. Acta Crystallogr C. 2010 Jan;66(Pt 1):o55-8. doi: 10.1107/S0108270109054249. Epub 2009 Dec 24. PubMed PMID: 20048427.

15: Yamamoto I. [Studies on the structure-activity relationship of allyl substituted oxopyrimidines searching for the novel antagonist or agonist of barbiturates to the sleep mechanism based on the uridine receptor theory--barbituric acid to uridine (part I)]. Yakugaku Zasshi. 2005 Jan;125(1):73-120. Review. Japanese. PubMed PMID: 15635282.

16: Krieglstein J, Mwasekaga S. Effect of methohexital on the relationship between hexokinase distribution and energy metabolism in neuroblastoma cells. Arzneimittelforschung. 1987 Mar;37(3):291-5. PubMed PMID: 3593443.

17: Hanke J, Krieglstein J. [Mechanisms of the protective effect of methohexital on cerebral energy metabolism]. Arzneimittelforschung. 1982;32(6):620-5. German. PubMed PMID: 7202367.

18: Budd RD, Yang FC, Utley KO. Barbiturates--structure versus RIA reactivity. Clin Toxicol. 1981 Mar;18(3):317-52. PubMed PMID: 7237963.

19: Hermann T, Mokrosz J, Bojarski J. Kinetics and mechanism of decomposition of some derivatives of 5-allylbarbituric acid. Part V. The course of hydrolysis of 5 allyl-5-(2'-hydroxypropyl)barbituric acid. Pol J Pharmacol Pharm. 1980 Sep-Oct;32(5):807-13. PubMed PMID: 6115373.

20: Dain JG, Bhuta SI, Coombs RA, Talbot KC, Dugger HA. Metabolism of butalbital, 5-allyl-5-isobutylbarbituric acid, in the dog. Drug Metab Dispos. 1980 Jul-Aug;8(4):247-52. PubMed PMID: 6105059.